12:59 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

RUNX1, RUNX3, CBFB and PMP22 as targets for neurofibromatosis

DISEASE CATEGORY: Cancer INDICATION: Neurofibromatosis Cell culture and mouse studies suggest promoting PMP22 expression, dual RUNX1/RUNX3 inhibition, or inhibiting the interactions of CBFB with RUNX1 and RUNX3 could help treat neurofibromatosis. In mouse neurofibroma Schwann...
20:54 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neuropathy Mouse and rat studies suggest inhibiting PMP22 could help treat Charcot-Marie-Tooth 1A (CMT1A) disease. In a mouse model of CMT1A, subcutaneous injection of an antisense oligonucleotide (ASO) targeting PMP22 increased motor nerve conduction...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Markers

This week in techniques Approach Summary Licensing status Publication and contact information Markers Three-gene signature predictive of indolent prostate cancer A three-gene signature could help identify patients who have less aggressive forms of prostate cancer....
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

Addex preclinical data

In a rat model of CMT1A, 10 mg/kg oral ADX71441 given every other day for 5 weeks followed by once-daily 5 mg/kg ADX71441 for 4 weeks down regulated PMP22 mRNA, reduced the number of hypo-myelinated...